U.S. Food and Staples Retail Stock News

Peoples Bancorp of North Carolina (PEBK) just closed out FY 2025 with fourth quarter revenue of US$24.6 million and EPS of US$1.25, alongside trailing 12 month revenue of US$89.1 million and EPS of US$3.74 that reflects 21.3% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from US$21.1 million in Q4 2024 to US$24.6 million in Q4 2025, while quarterly EPS shifted from US$0.67 to US$1.25. This sets up a story where improving margins and a...

KBRA recently assigned preliminary credit ratings to 56 classes of mortgage-backed notes from PMT Loan Trust 2026-CNF1, a prime RMBS transaction backed by 576 agency-eligible, conforming mortgage loans sponsored by PennyMac Corp., an indirect wholly owned subsidiary of PennyMac Mortgage Investment Trust. This fresh securitization highlights PennyMac Mortgage Investment Trust’s continued use of mortgage-backed markets to finance conforming, general QM loans and potentially broaden its...

U.S. Gold Corp recently advanced its CK Gold Project in Wyoming toward a Definitive Feasibility Study after securing US$31,000,000 in financing, while benefiting from record-high gold prices that enhance project economics and the perceived value of its Nevada and Idaho exploration assets. An interesting angle is how stronger gold prices can make mine-construction financing more attainable, potentially accelerating timelines for turning U.S.-based mineral resources into producing...

Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy. The results show sustained functional benefits in ambulatory Duchenne patients over 3 years with a manageable safety profile. No new safety issues were identified in the 3 year readout, addressing prior concerns around long term efficacy and safety. Sarepta Therapeutics focuses on genetic medicines for rare neuromuscular diseases, and...

If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock. The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years. Recent news around BridgeBio has centered on...

Piper Sandler Companies recently reported that over the past two years it has delivered strong annual growth in revenue, earnings per share, and tangible book value per share, all pointing to improved profitability and capital strength. What stands out is that earnings per share expansion has far outpaced revenue growth, implying meaningful efficiency gains and better operating leverage across the business. We’ll now examine how this outsized earnings growth, relative to revenue, may...

Chewy (NYSE:CHWY) has announced the retirement of its Chief Technology Officer, Satish Mehta. The leadership transition affects oversight of Chewy's technology platforms and product development efforts. Stakeholders are assessing what this change could mean for the company's future technology priorities. Chewy, trading at $31.43, has seen its share price under pressure, with a 7 day return of a 6.8% decline and a 1 year return of a 19.3% decline. Over 3 years, the stock has recorded a 27.3%...

Dynex Capital (DX) has wrapped up FY 2025 with Q4 total revenue of US$202.0 million and basic EPS of US$1.17, alongside trailing twelve month revenue of US$372.1 million and EPS of US$2.49. This sits next to a very large 190.8% earnings jump over the past year and an 11.4% annual earnings decline over five years. The company has seen quarterly revenue move from US$60.3 million in Q4 2024 to US$201.997 million in Q4 2025, while basic EPS shifted from US$0.61 to US$1.17 over the same period...

After a strong run, you might be wondering whether Karooooo is still reasonably priced or starting to look stretched at current levels. The stock last closed at US$50.84, with returns of 8.6% over the past week, 7.3% over the last month, 13.8% year to date, and 19.6% over the past year. This puts recent price action front and center for anyone thinking about value. Over the past three years, Karooooo has delivered a total return of 122.8%, which gives useful context to the shorter term moves...

Event context and recent price moves Delek US Holdings (DK) has been on investors’ radar after a recent pullback, with the stock down about 6% over the past month and about 26% in the past 3 months. See our latest analysis for Delek US Holdings. While the recent 30 day share price return of about 7% decline and 90 day share price return of about 26% decline suggest fading momentum, longer term total shareholder returns of 60% over one year and 72% over five years tell a different story. If...

Jabil (NYSE:JBL) announced a US$1b senior notes offering, aimed at reinforcing its capital structure. The company also revealed a new manufacturing collaboration with Eagle Harbor Technologies focused on advanced semiconductor fabrication. These updates highlight both a financing move and a shift toward deeper involvement in high-complexity semiconductor manufacturing. Jabil is known for contract manufacturing and supply chain services across electronics, healthcare, and other technology...

Navan has expanded its partnership and direct API integration with Booking.com, broadening access to lodging options for corporate travelers. The upgrade gives Navan customers access to more properties, including in less conventional destinations, along with exclusive discounted rates. Travel managers gain stronger oversight tools, aimed at improving policy compliance and cost control across corporate travel programs. For investors watching NasdaqGS:NAVN, the Booking.com expansion comes as...

Why NetApp Is On Investors’ Radar Today NetApp (NTAP) is back in focus after recent trading left the stock with a month return of about an 11% decline and a past 3 months return of roughly a 15% decline, inviting closer attention to its current valuation. See our latest analysis for NetApp. At around $98.81 per share, NetApp’s recent 7 day and 30 day share price returns of a 4.8% and 10.6% decline sit against a 1 year total shareholder return of a 15.9% decline. The 3 year and 5 year total...

PSB Holdings (PSBQ) closed out FY 2025 with fourth quarter revenue of US$13.5 million and EPS of US$0.97, rounding off a trailing twelve month run that produced revenue of US$51.4 million and EPS of US$3.32. Over the past year, revenue has moved from US$44.9 million to US$51.4 million and EPS has shifted from US$2.37 to US$3.32, setting up the current results against a period of rising profitability. With trailing net profit margin at 26.2% versus 21.9% a year earlier, the latest report...

DocuSign (NasdaqGS:DOCU) has introduced new AI powered eSignature tools for its Intelligent Agreement Management platform. The update focuses on summarizing complex contract terms and automating document preparation tasks. The features are designed to make agreements clearer for users and reduce manual work for businesses. DocuSign operates at the center of digital agreement workflows, helping companies move contracts and approvals online. The new AI tools fit into a wider push across...

Clover Health Investments (NasdaqGS:CLOV) is reporting strong customer growth for its Medicare Advantage plans and related technology solutions. The company is seeing an expanding free cash flow margin even as revenue has declined over the past two years. This mix of higher customer counts and improving cash generation, alongside revenue pressure, is a fresh development that investors are assessing. Clover Health focuses on Medicare Advantage insurance and technology driven care tools,...

In recent trading, DXP Enterprises has been caught up in past market volatility tied to shifting U.S. trade tensions and tariff threats, while investors also look ahead to an earnings report that is expected to show lower EPS alongside higher revenue. The stock’s moves highlight how external policy uncertainty can weigh on sentiment even when consensus expectations point to continued sales growth and constructive analyst rankings. We’ll now examine how trade-policy uncertainty and the...

If you are wondering whether Pathward Financial is still fairly priced or starting to look expensive at current levels, you are not alone. The stock recently closed at US$85.43, with returns of 13.5% over 7 days, 16.3% over 30 days, 18.9% year to date, 6.9% over 1 year, 76.7% over 3 years and 120.1% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on how Pathward Financial is positioned within the US...

Why Celsius Holdings Is Back on Investors’ Radar Celsius Holdings (CELH) is drawing fresh attention as investors react to rapid revenue growth, broader distribution across key channels, and operating margins around 20%, all alongside new leadership additions tied to major beverage industry experience. See our latest analysis for Celsius Holdings. After a mixed few months, with a 19.63% 1 month share price return offset by an 11.89% 3 month share price decline, Celsius Holdings now trades at...

Costco faces a class action lawsuit alleging false advertising over preservatives in its $4.99 rotisserie chicken. The complaint claims Costco misled shoppers about ingredients and challenges the accuracy of its product labeling. The case raises broader questions about transparency in food labeling and how retailers describe signature products. For investors watching NasdaqGS:COST, the lawsuit comes at a time when Costco shares trade around $977.67, with a 30 day return of 11.9% and a 3...

Why SkyWater Technology is on investors’ radar SkyWater Technology (SKYT) has drawn fresh attention after a sharp share price move, with the stock up about 78% over the past month and roughly 97% in the past 3 months. See our latest analysis for SkyWater Technology. That sharp 77.9% 1 month share price return and 96.7% 3 month share price return, from a latest share price of $32.35, sits alongside a 1 year total shareholder return of about 230%. This suggests momentum has been building...

TowneBank (TOWN) is on investors’ radar after recent share price gains over the past month and the past 3 months, prompting closer attention to how its current valuation lines up with fundamentals. See our latest analysis for TowneBank. The recent share price strength, including a 7.30% 30 day share price return and 8.82% year to date share price return to US$36.15, sits alongside a 5 year total shareholder return of 78.19%, pointing to momentum that has built over a multi year period. If...

FDA Breakthrough designation puts pemvidutide in focus Altimmune (ALT) has drawn fresh attention after the FDA granted Breakthrough Therapy Designation to its lead candidate pemvidutide for MASH, based on mid stage trial data showing significant disease resolution. See our latest analysis for Altimmune. The FDA Breakthrough Therapy news has arrived during a period of building momentum for Altimmune, with the 7 day share price return of 33.49% and year to date share price return of 61.25%...

If you are wondering whether Mastercard's current share price fairly reflects its long term potential, starting with a clear view of value can help you decide where it might fit in your portfolio. The stock closed at US$527.36, with a 2.2% decline over the last 7 days and a 9.0% decline over the last 30 days, while still showing longer term returns of 44.6% over 3 years and 68.8% over 5 years. Recent news coverage has focused on Mastercard's ongoing role in global digital payments and its...